US Patent 9982241 Recombinant HCMV and RHCMV vectors and uses thereof
Patent 9982241 was granted and assigned to Oregon Health & Science University on May, 2018 by the United States Patent and Trademark Office.
All edits
Edits on 8 Dec, 2023
Golden AI
Edits made to:
Article (+551 characters)
Article
Patent abstract
The recombinant rhesus cytomegalovirus (RhCMV) and human cytomegalovirus (HCMV) vectors of this invention encode heterologous antigens, such as pathogen-specific antigens or tumor antigens, which may be used, for example, for the treatment or prevention of infectious disease or cancer. The recombinant RhCMV or HCMV vectors elicit and maintain high level cellular immune responses specific for the heterologous antigen while including deletions in one or more genes essential or augmenting for CMV replication, dissemination or spread.
Edits on 1 Oct, 2023
Golden AI
Edits made to:
Infobox (+5 properties)
Infobox
Patent Inventor Names
Jay A. Nelson0
Klaus Frueh0
Louis Picker0
Michael A. Jarvis0
Scott G. Hansen0
Edits on 5 Jul, 2023
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 24 May, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 09982241 Recombinant HCMV and RHCMV vectors and uses thereof US Patent 9982241 Recombinant HCMV and RHCMV vectors and uses thereof
Infobox
Patent Number
09982241
Patent Number
9982241
Edits on 20 Jan, 2022
Golden AI
Edits made to:
Infobox (+9 properties)
US Patent 09982241 Recombinant HCMV and RHCMV vectors and uses thereof
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
09982241
Date of patent
May 29, 2018
Patent application number
14872756
Date Filed
October 1, 2015
Patent primary examiner
Find more entities like US Patent 9982241 Recombinant HCMV and RHCMV vectors and uses thereof
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
